Celularity has entered an exclusive manufacturing and commercial collaboration with Vesalius Longevity Labs to produce peptide active pharmaceutical ingredients in the United States under Vesalius’s Peptual brand. The work will take place at Celularity’s New Jersey facility and is intended to build a domestic supply platform for these ingredients.
- Celularity’s role: The company will provide manufacturing infrastructure and technical expertise for purification, processing, analytical testing and manufacture of the peptide ingredients.
- Production standards: The parties intend to make the ingredients in line with current good manufacturing practice standards.
- Supply-chain goals: The collaboration is designed to support consistent product quality and lot-level traceability, while increasing the resilience and accountability of the peptide-ingredient supply chain.
- Terms: The announcement does not provide financial terms, production volumes or a start date.
The collaboration gives Celularity a role in U.S.-based production for Vesalius’s Peptual platform. No further commercial or financial details were provided.